NCT00752427View on ClinicalTrials.gov

24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 30, 2004

Study Completion Date

November 30, 2005

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone ER OROS®

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00752427 - 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter